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Abstract
Background: Purified intravenous immunoglobulin (IVIG) obtained from the plasma of healthy humans is indicated
for the treatment of primary immunodeficiency disorders associated with defects in humoral immunity. IVIG
contains naturally occurring auto-antibodies, including antibodies (Abs) against b-amyloid (Ab) peptides
accumulating in the brains of Alzheimer’s disease (AD) patients. IVIG has been shown to alleviate AD pathology
when studied with mildly affected AD patients. Although its mechanisms-of-action have been broadly studied, it
remains unresolved how IVIG affects the removal of natively formed brain Ab deposits by primary astrocytes and
microglia, two major cell types involved in the neuroinflammatory responses.
Methods: We first determined the effect of IVIG on Ab toxicity in primary neuronal cell culture. The mechanisms-
of-action of IVIG in reduction of Ab burden was analyzed with ex vivo assay. We studied whether IVIG solubilizes
natively formed Ab deposits from brain sections of APP/PS1 mice or promotes Ab removal by primary glial cells.
We determined the role of lysosomal degradation pathway and Ab Abs in the IVIG-promoted reduction of Ab.
Finally, we studied the penetration of IVIG into the brain parenchyma and interaction with brain deposits of
human Ab in a mouse model of AD in vivo.
Results: IVIG was protective against Ab toxicity in a primary mouse hippocampal neuron culture. IVIG modestly
inhibited the fibrillization of synthetic Ab1-42 but did not solubilize natively formed brain Ab deposits ex vivo. IVIG
enhanced microglia-mediated Ab clearance ex vivo, with a mechanism linked to Ab Abs and lysosomal
degradation. The IVIG-enhanced Ab clearance appears specific for microglia since IVIG did not affect Ab clearance
by astrocytes. The cellular mechanisms of Ab clearance we observed have potential relevance in vivo since after
peripheral administration IVIG penetrated to mouse brain tissue reaching highest concentrations in the
hippocampus and bound selectively to Ab deposits in co-localization with microglia.
Conclusions: Our results demonstrate that IVIG promotes recognition and removal of natively formed brain Ab
deposits by primary microglia involving natural Ab Abs in IVIG. These findings may have therapeutic relevance in
vivo as IVIG penetrates through the blood-brain barrier and specifically binds to Ab deposits in brain parenchyma.
Background
Deposition of Ab peptides is the major hallmark of AD
in addition to neurofibrillary tangles formed by hyper-
phosphorylated tau [1]. The Ab deposits consist primar-
ily of fibrillized Ab1-40 and Ab1-42 peptides, the latter
being more prone to aggregation. The Ab deposits con-
taining Ab peptide oligomers, diffuse Ab deposits and
aggregated fibrillar Ab induce neurotoxicity and cogni-
tive defects, as demonstrated in vitro and in vivo [1-4].
The Ab neurotoxicity may be largely regulated by
microglia, the surveillant cells of the CNS [5], which
may possess double-faced actions of conducting both
pro-inflammatory and anti-inflammatory effects [6-9]. * Correspondence: Johanna.Magga@uef.fi
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has been shown to alleviate neurodegeneration and cog-
nitive defects in mouse models of AD [10-13]. There are
numerous potential mechanisms that may regulate Ab
levels in the brain. According to the peripheral sink
hypothesis, Ab Abs in the plasma extract Ab via equili-
brium in efflux of Ab across the blood-brain barrier
(BBB) [14]. In the brain parenchyma, the reduction of
Ab burden may be endogenously carried out by astroglia
[15,16] in addition to microglia, which have been
demonstrated to participate in both deposition of Ab
[2,17] as well as reduction of Ab burden by phagocytosis
or some other mechanisms [18-20]. Under certain cir-
cumstances, microglia-mediated Ab phagocytosis is
enhanced after Ab deposits are opsonized with active or
passive immunotherapy, and this Ab clearance is also
associated with alleviation of cognitive defects or AD-
related neuropathological changes [10-14,21]. Immuni-
zation can also remarkably alleviate cognitive defects
without reduction of Ab burden [22], possibly because
of enhanced peripheral clearance or sequestration of
soluble Ab peptides from the brain to blood [14,23-25].
Monoclonal Abs to Ab have also been shown to inhibit
fibrillization of synthetic Ab peptide in vitro [26],
thereby preventing the aggregation of Ab.
IVIG, purified immunoglobulin obtained from the
plasma of healthy humans is indicated for the treatment
of primary immunodeficiency disorders associated with
defects in humoral immunity. In addition, IVIG is used
as an anti-inflammatory therapy for many systemic dis-
eases, including diseases affecting the CNS [27].
Recently, a retrospective study suggested that previous
IVIG treatment is associated with a reduced risk of
developing AD and related disorders [28]. Furthermore,
administration of IVIG to eight patients with mild AD
led to transient, reproducible, and dose-dependent
increases in serum anti-Ab Ab titers in parallel with
increases in plasma Ab1-40 and Ab1-42 levels and
improvement in memory functions [29].
Naturally occurring Ab Abs or specific immune com-
plexes containing auto-Abs to Ab are significantly less
frequent in AD patients than those in age-matched con-
trols, suggesting that reduced levels of auto-Abs to Ab
could lead to increased Ab deposition in AD [30-33].
Recently it was reported that Ab Abs abundant in
human plasma are reactive against oligomeric Ab,b u t
the reactivity against oligomeric Ab assemblies declines
with age and advancing AD [34]. Furthermore, IgG was
detected in the brain and found to bind to brain Ab
deposits while AD patients with high IgG plaque label-
ing index had reduced plaque burden which was accom-
panied with an elevated level of phagocytic microglia
[35]. IVIG may serve as a potential therapy to compen-
sate the deprivation of naturally occurring Ab Abs in
AD that would alleviate the Ab-induced toxicity. Alter-
natively, IgG antibodies unrelated to specific Ab Abs
m a yh a v eb e n e f i c i a le f f e c t sa g a i n s tA b toxicity as IgG
has been shown to protect brain also against acute brain
injuries [36,37]. However, the detailed mechanisms how
IVIG treatment improves the AD pathology and cogni-
tive defects are unclear.
The potential and mechanisms-of-action of IVIG as an
anti-inflammatory agent for a broad range of diseases is
under intensive investigation. IVIG contains naturally
occurring auto-Abs, including Abs against Ab [38,39]
which are able to block synthetic Ab fibrillization and
prevent Ab-mediated neurotoxicity in vitro [39]. IVIG
has also been shown to dissolve pre-formed synthetic
Ab fibrils in vitro, as well as to promote synthetic Ab
uptake in BV-2 microglia, a murine microglia cell line
[40]. However, it is still unsolved whether IVIG could
actually dissolve natively pre-formed human Ab deposits
in brain and/or enhance the recognition and reduction
of these Ab deposits by primary microglia. Therefore, it
is unclear whether the beneficial effects of IVIG
observed in earlier in vitro studies using synthetic Ab
have true relevance in Ab deposition and its possible
reduction in AD.
In this study we demonstrate that IVIG prevents Ab
toxicity to hippocampal neurons and that the beneficial
effect of IVIG may be mediated by direct neuroprotection
as well as by enhanced microglia-mediated, but not astro-
cyte-mediated, clearance of natively formed diffuse
human Ab deposits in the brain. This microglia-mediated
clearance of Ab occurs by a mechanism involving Ab-
Abs present in IVIG and phagocytic degradation of Ab.
In line with the idea that IVIG treatment can result in
microglia-mediated Ab clearance, we demonstrate that
peripherally administered IVIG penetrates into the brain
parenchyma of transgenic AD mice and selectively binds
to Ab deposits which are co-localized and surrounded
with microglia.
Methods
Animals
The amyloid precursor protein and presenilin 1 trans-
g e n i c( A P P / P S 1 )b r e e d e rm i c ew e r eo b t a i n e df r o m
Johns Hopkins University, Baltimore, MD, USA (D.
Borchelt and J. Jankowsky, Department of Pathology),
and a colony was established at the National Laboratory
Animal Center, University of Eastern Finland. Briefly,
mice were created by co-injection of chimeric mouse/
human APP695 harboring the Swedish mutation
K595N/M596L and human PS1-dE9 (deletion of exon 9)
vectors controlled by independent mouse prion protein
promoter elements [41]. The double transgenic mice,
APP/PS1, were backcrossed to C57BL6/J for 10-12 gen-
erations. Age-matched wild-type littermates served as
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ment, and food and water were available ad libitum.
Animal experiments were conducted according to the
Council of Europe legislation and regulations for animal
protection and approved by the Animal Experiment
Committee in State Provincial Office of Southern
Finland.
IVIG
Purified IVIG (trade name Gammagard Liquid), pre-
pared from the plasma of healthy humans, was kindly
provided by Baxter Innovations GmbH (Vienna, Aus-
tria). The control IVIG, depleted of anti-Ab Abs with
affinity chromatography, was also provided by Baxter.
The concentration of Ab Abs is approximately 0.2%
of all IgGs present in IVIG [42]. The anti-Ab deple-
ted IVIG was determined to contain about 5% of
its naturally occurring Ab Abs. The molarity of IVIG
was counted based on the molecular weight of Ig,
150 000 Da.
Ab neurotoxicity in hippocampal neuronal culture
Primary hippocampal neuronal cultures from E18
C57BL mouse brains were prepared as described
previously [43,44]. Briefly, after dissection and papain-
dissociation the hippocampi were suspended in Dulbec-
co’s modified eagle medium (DMEM), 10% FBS with
penicillin-streptomycin (Gibco, Invitrogen) and plated
on poly-DL-ornithine-precoated (0.5 μg/μl; Sigma) 48-
well culture plates at 150 000 cells/cm
2 and cultivated
in humidified atmosphere at 37°C in 5% CO2. The next
day the medium was changed to serum-free Neurobasal
culture medium supplemented with 2% B27, 500 μM
glutamine, 25 μM glutamate, and penicillin-streptomy-
cin (Gibco, Invitrogen). To obtain ~90% pure neuronal
culture, cells were treated with 10 μM cytosine arabino-
side (AraC, Sigma) at days 2-4 to prevent proliferation
of other cell types. Thereafter, the whole medium was
changed for supplemented Neurobasal to remove AraC,
and in addition, one-third of the medium was changed
every 3-4 days for maintenance. The hippocampal
n e u r o n sw e r eu s e df o re x p e r i m e n t sa f t e r1 1d a y si n
vitro (DIV).
Ab1-42 (American Peptide) was dissolved to a stock
solution of 1 mg/ml in sterile water. Hippocampal neu-
rons were co-treated with freshly dissolved Ab1-42 and
IVIG for 24 h. Thereafter, the medium was collected
and analyzed for lactate dehydrogenase (LDH) release
(Sigma) according to the kit protocol. LDH assay mea-
sures membrane integrity as a function of the amount
of cytoplasmic LDH released into the medium. Hippo-
campal neurons were fixed with 4% formaldehyde and
stained with the bisbenzimide Hoechst 33342, (Sigma)
for detection of apoptotic/necrotic cells. The cell
viability was determined under the fluorescent micro-
scope (Olympus IX71 microscope with MT10 illumina-
tion system attached to DP70 digital camera, running
DP software, Olympus) based on the absence of con-
densed chromatin.
Ab fibrillization
Ab1-42 was dissolved to a stock solution of 1 mg/ml in
sterile water. We have previously shown that Ab1-42
starts immediately and spontaneously to oligomerize
and eventually fibrillize [44], being most toxic in oligo-
mer-rich form immediately after being dissolved. To
obtain fully fibrillized Ab, the dissolved peptide was
incubated at 37°C for 24 h. The oligomerization state of
Ab was analyzed with immunoblotting for human Ab
(clone 6E10, Signet, Covance) after cross-linking the
samples with glutaraldehyde as described previously
[44]. The fibrillary state of Ab has been confirmed with
electron microscopy as described previously [44].
The effect of IVIG on Ab fibrillization was studied by
incubating freshly solubilized 10 μMA b1-42 in the pre-
sence or absence of 5, 10 and 30 μMI V I Go r3 0μMo f
irrelevant human recombinant IgG (Baxter) as a control,
at 37°C for 24 h. PBS buffer was used as an additional
control. The concentration of the fibrillar Ab was quan-
tified fluorometrically using Thioflavin-T staining [45].
The samples were added to 2 μMT h i o f l a v i n - T( S i g m a )
solution in 50 mM glycine, pH 9.2. Fluorescence was
measured at excitation and emission wavelengths of 435
and 485 nm respectively.
To study whether IVIG could solubilize natively pre-
formed Ab deposits in brain, cryostat-cut brain sections
of aged (19 month old) APP/PS1 mice were incubated
i nt h ep r e s e n c eo ra b s e n c eo f2 0μMI V I Gi nex vivo
medium consisting of X Vivo 15 (Lonza), penicillin-
streptomycin and 2 mM L-glutamine (Gibco, Invitrogen)
for 7 days after which the medium was collected and the
Ab1-42 concentration was determined with Ab1-42
ELISA (Biosource). The brain sections were fixed with
4% formaldehyde in PBS for 30 min and analyzed for
Ab content. Nonspecific binding sites were blocked with
10% normal goat serum (NGS) in 0.1% PBS-T. The sec-
tions were reacted with pan-Ab Ab 3 μg/ml (Biosource)
in 1% NGS PBS-T overnight, followed by 10 μg/ml
Alexa568 secondary Ab (Molecular Probes) for 2 h at
room temperature (RT). The glass coverslips were
mounted onto microscope slides using Vectashield con-
taining nuclear stain DAPI (Vector Laboratories). The
sections were imaged with an Olympus AX70 micro-
scope attached to a digital camera (Color View 12 or
F-View, Soft Imaging System) running an Analysis
Software (Soft Imaging System) and quantified (Image
ProPlus, Media Cybernetics) for the Ab burden as an
indicator of solubilization of pre-formed Ab deposits.
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Mixed microglia cell culture was prepared from P0-P1
C57BL mouse pups as described [46]. Briefly, the cor-
tices and midbrain were dissected out and meninges
were removed. The tissues were dissociated with trypsin
and the cells were eventually resuspended into DMEM,
10% FBS, 100 U/ml penicillin-streptomycin and 2 mM
L-glutamine (Gibco, Invitrogen). The cells were plated
on cell culture flasks coated by poly-L-lysine (PLL,
Sigma) and cultivated in humidified atmosphere at 37°C
in 5% CO2. The medium was changed after two days
and thereafter every 2-3 days of cultivation. The loosely
attached microglia were harvested after 12 DIV by shak-
ing the flasks at 120 rpm for 10-15 min at 37°C in an
orbital shaker. For ex vivo experiments, microglia were
resuspended in serum-free X Vivo 15 medium (Lonza)
supplemented with penicillin-streptomycin and 2 mM
L-glutamine.
The ex vivo Ab degradation assay was modified from
Koistinaho et al. [15]. Aged APP/PS1 mice were per-
fused with heparinized saline and brain hemispheres
were frozen on dry ice. Cryostat-cut (Leica) 10-μm-thick
sagittal brain sections were mounted on PLL-coated
glass coverslips and transferred onto 24- or 48-well cell
culture plates and stored at -20°C until use. Brain sec-
tions were thawed shortly before use and incubated with
IVIG for 1 h at 37°C, after which the cells were applied
onto the brain sections, 250 000 cells/cm
2 with or with-
out IVIG. After 24 h of incubation, the sections were
fixed and immunostained as described above. The sec-
tions were quantified as described above for the amount
of remaining Ab immunostaining (Ab burden) as an
indicator for Ab clearance by the cells. IVIG concentra-
tions higher than 20 μM may cause an excess dilution
of the cell culture medium and may not be relevant for
in vivo conditions. Thus, IVIG concentrations ≤20 μM
were used.
To study IVIG interaction with Ab deposits in micro-
glia-mediated Ab clearance, the brain sections were first
incubated with IVIG for 1.5 h at 37°C and after wash
out of any unbound IVIG, the microglia were applied as
described above. After 24 h of incubation, reduction of
Ab burden was quantified as described above.
To elucidate the contribution of and the effect of IVIG
on lysosomal degradation, the major intracellular pro-
tein degradation pathway in microglia-mediated Ab
clearance, microglia ex vivo assay with or without IVIG
was performed in the presence of 500 nM bafilomycin
A1 (Baf) (Sigma) to inhibit the lysosomal degradation
pathway in microglia. After 24 h of incubation, the
reduction of Ab burden was quantified.
The analysis of co-localization of Ab deposits and
m i c r o g l i aw a sp e r f o r m e db yi m a g i n gt h es a m es i t eo f
the brain section after exciting Alexa568 and DAPI
fluorescence, respectively. The figures were merged with
Adobe Photoshop. The count the number of microglia
the same site of sections were imaged as described
above and the cells were counted based on the nuclear
stain DAPI present in the mounting medium.
Cell viability was determined by resazurin assay. After
24 h of incubation, 10 μM resazurin (Sigma) was applied
into cell culture medium and incubated for 4 h. Med-
ium samples were collected into 96-well plate and mea-
sured with excitation 544 nm, emission 590 nm (Victor
Wallac).
Degradation of brain Ab by primary astrocytes
Adult astrocyte cell culture was prepared as described
before [15]. Briefly, hippocampi and cortices were iso-
lated from 6-8-week-old C57BL mice and the tissues
were dissociated with trypsin followed by Percoll
(Sigma) centrifugation. The cells were eventually
resuspended into DMEM/F12, 10% FBS, 100 U/mL
penicillin-streptomycin and G5 supplement (Gibco, Invi-
trogen), plated onto PLL-coated cell culture flasks and
cultivated in humidified atmosphere at 37°C in 5% CO2
for several passages. Before the experiments the glial cell
cultures were shaken at 200 rpm for 2 h at 37°C to
remove microglia.
For ex vivo experiments, astrocytes were re-suspended
in serum-free DMEM/F12 medium, 0.2% BSA (Sigma),
100 U/ml penicillin-streptomycin and G5 supplement
and applied onto the brain sections at 150 000 cells/cm
2
as described above.
Penetration of IVIG into the brain
To study the brain access of human IVIG, 4-month-old
APP/PS1 mice or their wild-type littermate controls
received i.p. injections of 1.0 g/kg of 10% IVIG or
e q u a lv o l u m e( 1 0m l / k g )o fs a l i n e .T h es h o r t - t e r m
injections (1-3 weeks) were administered twice a week
while the long-term injections were given once per
week.
Intrahippocampal injection of IVIG
Intrahippocampal injections were performed as previously
described [47]. Briefly, IVIG was injected unilaterally
(200 μgi nt h ev o l u m eo f2μl) into the hippocampi of
16-month-old APP/PS1 mice. The animals were transcar-
dially perfused 3 days later, and the brains were applied
to immunohistochemistry.
Immunohistochemistry
At the end of the study the mice were anesthetized with
an anesthetics cocktail consisting of 105 mg/kg pento-
barbiturate and 425 mg/kg chloral hydrate, and trans-
cardially perfused with heparinized saline. Brains
were retrieved rapidly and immersion fixed in 4%
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sucrose in 0.1 M PB overnight and stored at -70°C until
further processed. Coronal brain sections, 35 μmi n
thickness, were cut with a freezing-sliding microtome at
the level of the septal (dorsal) hippocampus. For human
IgG staining the sections were treated with 0.1% H2O2
in methanol, and incubated overnight with rabbit
anti-human HRP-labelled Ab (DAKO, 1:7500 in TBS
containing 0.25% Triton X-100 (TBS-T), pH 7.6. Immu-
noreactivity was visualized with H2O2 and 0.25% nickel
enhanced diaminobenzidine (Sigma).
For triple staining to study co-localization of Ab,
microglia and human IgG, free floating sections were
extensively washed with 0.1 M TBS, pH 7.4 and non-
specific binding sites in the tissue were blocked with 5%
normal donkey serum in TBS, to which 0.3% Triton X-
100 had been added (NDS-TBS-T), for 1 h. The sections
were then incubated overnight with a mixture of bioti-
nylated monoclonal mouse anti-Ab17-24 (clone 4G8,
Covance, 1:100 in NDS-TBS-T) and rabbit-anti-Iba 1
(Wako Chemicals GmbH, Neuss, Germany, 1:400).
Next, the sections were rinsed with TBS and applied to
a cocktail of highly purified, carbocyanine (Cy)-conju-
gated secondary Abs (all from Jackson ImmunoRe-
search, West Grove, PA, 20 μg/ml in TBS containing 2%
BSA): Cy3-coupled streptavidin, Cy5-coupled donkey-
anti-rabbit IgG and Cy2-coupled donkey anti-human
IgG. The sections were examined with a confocal laser-
scanning microscope (LSM10 Meta, Zeiss) as described
before [48]. The Cy5-immunolabelling was color-coded
in blue.
Statistical analysis
The data are expressed as mean ± SD and were ana-
lyzed with SPSS software using Student’s T-test or one-
way ANOVA when appropriate, followed by Dunnett’s
or Tukey’s post hoc t e s t .*( p<0 . 0 5 ) ,* *( p<0 . 0 1 ) ,* * *
(p < 0.001).
Results
IVIG protects primary hippocampal neurons against Ab1-
42 toxicity
When mouse hippocampal neuronal cultures containing
90% of neurons were exposed to 5 or 10 μM oligomer-
rich Ab1-42 preparation (Figure 1A) for 48 h, significant
neuronal death was observed by LDH release into the
cytoplasm and by counting surviving neurons (p <
0.001, Figure 1B and 1C). Co-administration of 10 μM
IVIG reduced the toxicity of 10 μMA b1-42, when LDH
release was measured (p < 0.05, Figure 1B), and 5 μM
IVIG completely blocked the toxicity of 5 μMA b1-42,
when viable cell count was recorded (p < 0.001, Figure
1C). IVIG treatment alone posed no toxicity to primary
neuronal cells (Figure 1B).
IVIG prevents Ab1-42 fibrillization to the same extent as
irrelevant IgG and does not solubilize natively formed
brain Ab deposits
Potential mechanisms for IVIG-induced neuroprotection
against Ab-induced cell death include interaction of
IVIG with Ab1-42 peptides by preventing oligomeriza-
tion and further fibrillization of Ab1-42, or solubiliza-
tion of pre-formed Ab1-42 fibrils/aggregates. When
Ab1-42 was taken into aqueous solution, Ab1-42 started
to oligomerize immediately, reaching a fully aggregated
state after 48 h of incubation (Figure 1A) as we have
also previously shown [44].
When 10 μMA b1-42 was incubated in the presence
of IVIG, fibrillization of Ab1-42 was reduced as deter-
mined with Thioflavin-T staining (Figure 1D). However,
the effect of IVIG on Ab1-42 fibrillization was not con-
centration-dependent and did not differ from the effect
of irrelevant human IgG. This suggests that the reduc-
tion of Ab1-42 fibrillization was not due to any specific
immunoglobulins present in IVIG.
To test whether IVIG could solubilize natively formed
human Ab deposits in brain, sections of aged APP/PS1
m o u s eb r a i n sw e r ei n c u b a t e dw i t h2 0μMI V I Gf o r
seven days and the medium was collected for quantifica-
tion of solubilized Ab1-42 with ELISA. In addition, the
brain sections were analyzed for the possible reduction
of Ab b u r d e ni nt h et i s s u eb yA b immunostaining. We
observed no effect of IVIG on the amount of Ab found
in the media as an indicator of the solubilization of
Ab1-42 from the brain sections (Figure 1E) or on total
Ab burden in the brain sections (Figure 1F).
IVIG specifically promotes microglia-mediated clearance
of brain Ab
When microglia were applied on top of unfixed cryo-
stat-cut brain sections prepared from aged APP/PS1
mice, and Ab b u r d e nw a sq u a n t i f i e da sA b immunor-
eactivity covering the hippocampal area of the brain sec-
tion, we observed a reduction of human Ab burden
to 86% when compared to control sections (p < 0.05,
Figure 2A and 2C). The analysis was focused on hippo-
campal brain areas of the brain sections due to region-
specific and even distribution of human Ab within those
areas, making comparisons between the sections feasible.
Twenty micromolar IVIG further promoted the ability
of microglia to reduce Ab burden to 68% from that of
control sections (p < 0.05) (Figure 2A and 2C). Based
on the co-localization of Ab immunoreactivity and
DAPI nuclear staining, the reduction of Ab was also
seen as Ab-free cavities in the brain sections at sites of
cultured microglia cell bodies (Figure 1D). IVIG per se
did not interfere with the subsequent detection of Ab
immunoreactivity (total Ab burden 11.3 ± 0.8% in con-
trol and 10.8 ± 1.1% in 20 μM IVIG treated sections,
Magga et al. Journal of Neuroinflammation 2010, 7:90
http://www.jneuroinflammation.com/content/7/1/90
Page 5 of 15p > 0.05), confirming that the reduction of Ab immu-
noreactivity indeed represents the reduction of Ab bur-
den in the brain tissue.
Primary astrocytes obtained from adult but not neona-
tal mouse brain has been shown to participate in the
removal of Ab from the brain [16]. When the ex vivo
assay was performed with adult mouse astrocytes, a
significant reduction of Ab burden to 86% of control
(Figure 2B p < 0.01) was observed, as previously
described [15]. However, IVIG up to 20 μM concentra-
tion did not promote the astrocyte-mediated Ab clear-
ance (Figure 2B). The inability of IVIG to enhance
astrocyte-mediated Ab clearance was not due to
prevention of astrocyte clustering which has been pre-
viously shown [15] to be required for Ab clearance by
these cells (data not shown).
The microglia-mediated reduction in brain Ab burden
w a sm o r ee v i d e n ti nr e g i o n sc o n t a i n i n gt h eh i g h e s t
amount of Ab-immunoreactive material, particularly in
the subiculum, which showed accumulation of both dif-
fuse and more dense Ab deposits. Quantifying immunor-
eactivity in the subiculum, we observed that microglia
reduced Ab burden to 73% of control sections (p < 0.05,
Figure 3A). Twenty micromolar IVIG further promoted
the microglia-mediated reduction of Ab burden to 47%
(p < 0.05, Figure 3A). The reduction of Ab was also
Figure 1 IVIG protects primary hippocampal neurons against Ab1-42 toxicity. Freshly solubilized 5 μMA b1-42 (Ab oligomer rich
preparation) was incubated for 0 or 48 h, cross-linked to preserve the peptide structure and analyzed with western blotting with an anti-Ab
antibody (6E10). Freshly solubilized Ab1-42 consisted of monomers, dimers, various forms of oligomers and aggregates with larger molecular
weight (Mw). After 48 h of incubation, low Mw forms of Ab1-42 were reduced while high Mw aggregates were detected (A). Mw of Ab1-42
monomer is 4.5 kDa. Mouse hippocampal neurons were exposed to freshly solubilized Ab1-42. After 48 h of incubation, the cytotoxicity was
determined with a defect in cell membrane integrity and the presence of condensed chromatin in nuclei. Ab1-42 was highly cytotoxic (B, C) in
micromolar concentrations (n = 3, p < 0.001). IVIG reduced Ab1-42-induced neurotoxicity by the terms of cytoplasmic LDH release (B, n = 3, p <
0.05) and the number of apoptotic/necrotic cells (C, n = 3, p < 0.001). The effect of IVIG on Ab fibrillization was studied by incubating freshly
solubilized 10 μMA b1-42 in the presence of IVIG or irrelevant human recombinant IgG (ctrl IgG) for 24 h and quantifying fibrillar Ab
fluorometrically with Thioflavin-T staining. IVIG reduced Ab1-42 fibrillization (D, p < 0.001, n = 3) but this was not concentration-dependent and
also occurred in the presence of an irrelevant IgG (D, p < 0.001, n = 3). To study the effect of IVIG on solubilization of natively formed brain Ab
deposits, unfixed cryostat-cut hippocampal brain sections prepared from aged APP/PS1 mice were incubated with 20 μM IVIG for 7 days. IVIG
did not solubilize pre-formed Ab deposits; the release of Ab into the medium was not increased (E, p > 0.05, n = 6) while Ab immunoreactive
area in the brain sections was not decreased (F, p > 0.05, n = 6), as determined with ELISA and immunostaining, respectively.
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microglia cell bodies (Figure 3B). Furthermore, we dis-
c o v e r e dt h a td i f f u s eA b immunoreactivity was greatly
reduced and nearly disappeared when incubated in the
presence of microglia and 20 μM IVIG (Figure 3B).
To exclude the possibility that IVIG induced microglia
proliferation and thereby enhanced microglia-mediated
clearance of Ab, we counted the microglia cells at the 24
h time point (data not shown) at the end of the ex vivo
assay from images taken exactly from the same site of the
brain section that was used to quantify Ab clearance. The
enhanced clearance of Ab was not due to the increased
number of microglia in response to IVIG. Moreover,
IVIG had no effect on cell viability as studied with resa-
zurin assay measuring cellular metabolism (Figure 3C).
Mechanisms of microglia-mediated clearance of brain Ab
We next examined whether the effect of IVIG on Ab
clearance was dependent on anti-Ab Abs present in IVIG.
The ex vivo assay was therefore performed in the presence
of IVIG depleted for Ab Abs (depleted IVIG). Microglia
were able to reduce Ab burden in the presence of IVIG
Figure 2 IVIG promotes microglia-mediated clearance of natively formed Ab deposits.I na nex vivo assay, neonatal mouse microglial cells
were incubated on top of APP/PS1 brain sections. After incubation period of 24 h, the Ab burden was quantified by Ab immunostaining.
Microglia alone reduced Ab burden ex vivo (A, C, n = 6-8, p < 0.05) as quantified from the whole hippocampus area. IVIG further promoted
microglia-mediated Ab clearance (A, C, n = 6-8, p < 0.05). The reduction of Ab was observed as Ab-free cavities in the brain sections at sites of
cultured microglia cell bodies, visualized with DAPI, as exemplified for the subiculum (D). When the ex vivo assay was performed for adult mouse
astrocytes, we observed a significant reduction of Ab burden (B, n = 6-8, p < 0.01), quantified from the whole hippocampus area, but no
promotion of Ab clearance with up to 20 μM IVIG (B, n = 6-8). Scale bars 200 μm (C) and 50 μm (D).
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Page 7 of 15and depleted IVIG to 26% (p < 0.001) and 62% (p < 0.05)
of control, respectively (Figure 4A and 4B). However, the
microglia-mediated clearance of Ab was significantly
diminished (p < 0.05) in the presence of depleted IVIG in
comparison to IVIG, suggesting that Ab Abs present in
IVIG are further promoting Ab clearance (Figure 4A). To
reveal whether binding of certain components of IVIG
preparation was enough to induce enhanced Ab clearance
by microglia, the pre-incubation of brain sections with
IVIG was followed by wash out of any unbound IVIG
prior to addition of microglia reduced Ab burden to 44%
(p < 0.001) of control (Figure 4A). In addition, following
IVIG wash out microglia did not significantly differ from
IVIG-treated microglia in their capacity to reduce Ab bur-
den. These results suggest that interaction of IVIG with
Ab deposits may be sufficient to promote Ab clearance by
microglia (Figure 4A and 4B).
To study the role of lysosomal degradation in micro-
glia-mediated Ab clearance, we performed the ex vivo
assay in the presence of Baf, an inhibitor of vacuolar H
+
ATPase (V-ATPase). Baf disrupts the lysosomal mem-
brane proton pump that maintains the low intralysoso-
mal pH needed for normal lysosomal activity [49]. In
the presence of both Baf and microglia, Ab deposits
remained mostly intact showing that intralysosomal pH
and anticipated inactivation of lysosomal proteases by
Baf prevented the ability of microglia to clear brain Ab
(p > 0.05, Figure 5A and 5B). IVIG was partially able to
restore microglia-mediated Ab clearance halted by Baf
as IVIG-enhanced microglia-mediated clearance of Ab
did not significantly decay when Baf was administered
(p > 0.05, Figure 5A). In the presence of Baf, IVIG
enhanced microglia-mediated Ab clearance predomi-
nantly from the sites of diffuse Ab deposits (Figure 5B).
These results suggest that the IVIG-enhanced Ab clear-
ance involves Ab uptake by microglia and is dependent
on intracellular lysosomal degradation.
IVIG penetrates into the brain and specifically binds Ab
deposits
Finally, we tested whether the cellular mechanisms of
Ab clearance observed in vitro have potential relevance
in vivo and dosed a few APP/PS1 mice i.p with IVIG or
saline starting at the age of 4 months. The concern was
whether human IVIG is able to cross the BBB to reach
brain parenchyma in effective concentrations. After
transcardial perfusion with saline to abolish any possible
interference with IVIG present in the blood, the IVIG
was identified from mouse brain sections with anti-
human IgG. IVIG penetrated the BBB as evidenced with
intensive anti-human IgG staining in the mouse hippo-
campus (Figure 6A). There was a clear anterior-poster-
ior gradient with the highest immunoreactivity at the
septal end of the hippocampus adjacent to the choroid
plexus. In addition, strong immunoreactivity was
observed lining the ventricles (Figure 6A). The intensity
of anti-human IgG immunoreactivity increased with the
duration of IVIG treatment (Figure 6C). Human IgG
immunolabeling was also observed in wild-type mice,
but to a lesser extent, suggesting that the BBB is more
leaky in APP/PS1 mice (data not shown). When few
APP/PS1 mice were injected with IVIG i.v., stronger
immunoreactivity was detected in the hippocampus than
after i.p. administration, suggesting that a higher con-
centration of IVIG available in the blood leads into a
higher rate of penetration through the BBB, favoring the
i.v. administration route (data not shown).
In the hippocampus, Ab deposits appeared as stippled
patterns of aggregated material covered with human IgG
immunoreactivity (Figure 6D), which was not observed
in IVIG treated wild type mice. When IVIG was injected
directly into the hippocampus, homogenous IgG immu-
noreactivity was observed (Figure 6E) similar to the IgG
Figure 3 IVIG promotes miroglia-mediated clearance of diffuse
Ab deposits. Within the hippocampus the microglia-mediated
reduction in Ab burden was the most evident in the subiculum
which displayed both dense (arrows) and diffuse (arrowheads) Ab
deposition (B). We observed primary microglia to reduce Ab burden
from the subiculum (A, n = 15, p < 0.05). IVIG further promoted the
microglia-mediated clearance of Ab (A, n = 15, p < 0.05). Diffuse Ab
deposits (arrowheads) were greatly reduced and nearly disappeared
when incubated in the presence of microglia and 20 μM IVIG (B).
Ab-free cavities, present in the brain sections incubated with
microglia or microglia and IVIG, are shown with asterisks (*). IVIG did
not affect cell proliferation or viability as measured with cellular
metabolic activity (C). Scale bar 50 μm.
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administration (Figure 6A). After the local intrahippo-
campal injection, IgG immunoreactivity was defined
within the injected brain hemisphere and IgG immunor-
eactivity was not observed lining the ventricles (Figure
6E). After intrahippocampal injection, IVIG appeared as
stippled patterns of aggregated material covered with
human IgG immunoreactivity (Figure 6E). Some human
IgG immunoreactive spots were also positive for Congo
Red staining, as a label for b-sheet structures in dense
core Ab deposits (data not shown). Finally, we verified
whether IVIG interacts with brain deposits of human-type
Ab in transgenic mice after peripheral administration of
IVIG. A closer examination with confocal microscopy
revealed co-localization of human IgG and Ab deposits
(Figure 7A, B and 7D), surrounded by increased number
of microglia (Figure 7C and 7D). Very low levels of IVIG
in areas devoid of Ab suggests a highly specific interaction
of IVIG with Ab deposits in vivo.
Discussion
IVIG has been proposed as a potential therapy for AD
and it has recently been shown to alleviate AD pathol-
ogy in an 18-month study carried out with 8 patients
with mild AD [29]. However, the exact mechanism how
IVIG treatment may improve the AD pathology is
unclear. Our study demonstrates that - in addition to
neuroprotection towards Ab toxicity - IVIG enhances
microglia-mediated but not astrocyte-mediated Ab
clearance. Immunoglobulins in general seem to reduce
Ab toxicity, and this beneficial effect is significantly
enhanced by Ab specific Abs. We demonstrate that per-
ipherally administered IVIG penetrates into the brain of
transgenic mice mimicking human AD pathology and
selectively binds to Ab deposits in the brain parench-
yma. Ab deposits co-localized with IVIG are also tightly
surrounded with Iba-1 positive microglia, demonstrating
notable relevance in vivo.
The accumulation of Ab within the brain of AD
patients reflects an imbalance between the deposition of
Ab and its clearance from the brain parenchyma, lead-
ing to pathological events including neurotoxicity and
inflammation. We performed neurotoxicity studies with
freshly solubilized Ab1-42, modeling Ab toxicity in the
presence of Ab oligomers and fibrils, as we and others
have described before [44,50]. IVIG or purified Ab Abs
of IVIG have been shown to inhibit neurotoxicity
induced by Ab oligomers in rat cortical neurons [39]
and N2A secondary cells [51]. We demonstrate IVIG to
reduce Ab1-42 induced neurotoxicity in primary mouse
Figure 4 Promotion of microglia-mediated clearance of Ab is dependent on Ab antibodies in IVIG. The depletion of Ab antibodies from
IVIG significantly compromised the IVIG-promoted microglia-mediated Ab clearance (A, n = 5-6, p < 0.05) as imaged in the subiculum (B).
Preincubation of brain sections with 20 μM IVIG followed by wash out of any unbound IVIG prior to addition of exogenous primary microglia
conserved microglia-mediated Ab clearance (A, B, n = 5-6, p < 0.001) that did not significantly differ from the ex vivo incubation in the presence
of IVIG throughout the assay (n = 5-6, p > 0.05). Dotted line represents the Ab immunoreactive area in intact hippocampal brain sections
incubated without microglia. The statistical significance of Ab clearance in comparison to intact brain section incubated without microglia is
shown as asterisks below the dotted line, indicating the respective p-values. Scale bar 100 μm.
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area typically affected in AD. Britschgi et al. [34]
reported that IgG purified from an individual AD
patient or a healthy non-demented control reduced Ab
neurotoxicity in a similar manner.
Ab deposits are reduced in transgenic mouse models of
AD via several mechanisms: (i) the inhibition of Ab fibril-
lization by Ab binding to Ab [26,52], (ii) glial cell mediated
clearance of Ab, including microglia-mediated phagocyto-
sis of opsonized Ab deposits [13,21,53], and (iii) the per-
ipheral sink route in which Ab Abs in the plasma extract
Ab via equilibrium into the efflux of Ab across the BBB
[14]. It should be noted here, that different origin of IVIG
preparations may account for binding of Ab species to
varying extent [54,55] causing a possible source of varia-
tion between different studies. Abs purified from IVIG
have been shown in vitro to inhibit the fibrillization as
well as to dissolve the preformed fibrils of Ab25-35, Ab1-
40 and Ab1-42 [39]. In addition, IVIG itself without
further purification steps was shown to dissolve pre-
formed Ab1-40 fibrils [39]. We have widely used an Ab1-
42 oligomerization and fibrillization model in our previous
Ab neurotoxicity studies [44,56,57]. Utilizing this model,
we observed IVIG to modestly reduce synthetic Ab1-42
fibrillization as detected with Thioflavin-T stain. This find-
ing is in line with previous studies with IVIG in Ab1-42
fibrillization [39]. However, we found this was not due to
any specific components present in IVIG since it also
occurred upon application of an irrelevant human recom-
binant control Ab, suggesting a mechanism independent
of Ab Abs and possibly partly characteristic to Ab frag-
ments in general. Furthermore, we observed no effect of
IVIG on solubilization of natively formed human Ab
deposits from APP/PS1 mouse brain sections. Besides
detecting no solubilization of Ab into the medium, we
observed no effect of IVIG on Ab burden quantified from
APP/PS1 mouse brain sections either. Since IVIG had no
additional effect on Ab1-42 fibrillization when compared
to irrelevant IgG, we suggest IVIG to have a direct effect
on neuronal cells to reduce Ab1-42 toxicity, or indirect
protection via neutralization of Ab1-42.
IVIG has previously been shown to enhance the
uptake of exogenously provided fibrillar Ab in BV-2
cells, a secondary cell line model for microglia [40].
Instead of determining Ab uptake, we investigated the
phagocytosis of Ab by primary mouse microglia in an ex
vivo assay, where the clearance of natively deposited
brain Ab was studied. The clearance of Ab by primary
microglia has been shown to occur predominantly after
opsonization of Ab deposits requiring their decoration
with Abs for consequent recognition by microglia
[10-14,21]. We found primary microglia to reduce Ab
burden without any preceding opsonization step
required. Moreover, we discovered IVIG to further
Figure 5 Promotion of microglia-mediated clearance of Ab is
dependent on lysosomal degradation. To study the role of
lysosomal degradation in microglia-mediated Ab clearance, the ex
vivo assay was performed in the presence of Baf, an inhibitor of
lysosomal degradation pathway. Baf inhibited microglia-mediated
Ab clearance (A, n = 3-6) as Ab deposits remained mostly intact in
sections treated with Baf (B). IVIG could partially restore microglia-
mediated Ab clearance halted by Baf. In the presence of Baf, 20 μM
IVIG treatment resulted in low clearance and mostly of diffuse Ab
deposits only (A, B, n = 3-4, p < 0.05). Dense (arrows) and diffuse
(arrowheads) Ab deposits are shown in the subiculum. Scale bar 50
μm.
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dent manner. In addition, the pre-treatment of brain
sections with IVIG and wash-out of unbound IVIG
before application of microglia was sufficient to enhance
the clearance of Ab deposits. This suggests that interac-
tion of IVIG with the Ab deposits may be sufficient to
promote Ab clearance by microglia. Furthermore, the
microglia-mediated clearance of Ab was significantly
reduced in the presence of depleted IVIG in comparison
to IVIG, suggesting that Ab Abs present in IVIG partici-
pated in Ab clearance. The ability of IVIG to induce
promotion of Ab clearance appears to be specific for
primary microglia, since we found no further enhance-
ment of Ab clearance by primary astrocytes.
Reduction of diffuse Ab deposits occurred at sites of
microglial cell body, where cavities in layers of human
Ab were seen to form. This phenomenon resembled
“moth-eaten” Ab plaques previously described in vivo
[58] showing special characteristics of microglia-
mediated Ab clearance. Earlier reports suggest that
microglia express proteases such as MMPs which could
degrade Ab extracellularly [59-61] and that IVIG
induces expression of MMP-9 in microglia [62]. When
ex vivo brain sections were incubated in the presence of
microglia-conditioned and microglia plus IVIG-condi-
tioned medium, we observed no significant reduction of
brain Ab burden (data not shown), suggesting that
extracellular proteases secreted by microglia were not
Figure 6 Human IgG immunoreactivity is detected in the brain after peripheral administration of IVIG. To study whether IVIG could
penetrate the BBB to reach brain parenchyma, APP/PS1 mice were injected i.p. with IVIG 1 g/kg or saline starting at the age of 4 months. The
IVIG was identified from cryostat-cut mouse brain sections with anti-human IgG. IVIG penetrated BBB as evidenced with intensive human IgG
staining in the mouse hippocampus (A) with a clear anterior-posterior gradient with the highest immunoreactivity at the septal end of the
hippocampus adjacent to the choroid plexus. Also, strong immunoreactivity was observed lining the ventricles (A). The intensity of human IgG
immunoreactivity was increased with the duration of IVIG treatment from 1 to 14 weeks of IVIG admininistration (C). Saline-treated mice were
devoid of specific immunoreactivity for anti-human IgG (B). In the hippocampus, Ab deposits appeared as stippled patterns of aggregated
material covered with immunoreactivity for human IgG (black arrows) (D). After a single intrahippocampal injection of IVIG the IgG
immunoreactivity was spread homogeneously throughout the hippocampus (E) while stronger IgG immunoreactivity was observed as stippled
patterns (E). Scale bars 200 μm (A, B, E) and 50 μm (D).
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mediated Ab clearance.
Cultured microglia have been shown to internalize Ab
and deliver it to lysosomes [63] where most non-selec-
tive protein degradation takes place. Baf, an inhibitor of
V-ATPase, disrupts the maintenance of intralysosomal
low pH [49]. We observed that Ab deposits remained
mostly intact in sections with Baf, indicating that intra-
lysosomal pH and anticipated inactivation of lysosomal
proteases by Baf affected the capability of microglia to
clear Ab. However, even in the presence of Baf, IVIG
treatment resulted in microglia-mediated clearance
mostly from diffuse Ab deposits, suggesting that IVIG
may potentiate microglia-mediated Ab clearance by
counteracting lysosomal deficits in microglia. In addi-
tion, inactivated microglia have weakly acidic lysosomes,
and lysosomal acidification during activation of micro-
glia is required for Ab degradation by microglia [64].
Thus our results suggest that Ab clearance occurs by
lysosomal degradation and boosting the lysosomal activ-
ity of microglia, potentially by IVIG, could increase Ab
clearance.
Recently, a receptor for anti-inflammatory activity of
IVIG was identified. Sialylated IgG Fc fragments in IVIG
were demonstrated to bind to SIGN-R1, a receptor on
mouse splenocytes, resulting in secretion of soluble anti-
inflammatory mediators that regulate macrophage activ-
ity [65]. However, since our model based on isolated
microglia from the CNS, this is not likely the mechan-
ism for IVIG activity. Generally, IVIG has been pro-
posed to regulate the activating and inhibitory FcgRo n
macrophages to modulate inflammation [27]. Since the
FcgR-mediated effect would rather suppress the inflam-
matory pathways, including phagocytosis, this is not
likely the mechanism explaining the IVIG-enhanced
phagocytosis in microglia. In the presence of IVIG, BV-
2 microglia display ramified morphology with high
expression of activation marker CD45, suggesting that
IVIG induces a specific activation pattern on microglia
[40]. Furthermore, it has been shown that intracranial
Ab Ab administration leads into a biphasic clearance of
Ab deposits [66]; first a rapid removal of diffuse Ab
deposits, and second the removal of compact Ab depos-
its associated with a transient activation of microglia.
We found IVIG to enhance microglia-mediated clear-
ance of diffuse Ab largely dependent on Ab Abs.
Unmodified immunoglobulins show a low tendency to
penetrate through the BBB [67], but in certain condi-
tions such as specific stages of diseases and in senes-
cence, immunoglobulins have easier access into the
brain [13,68]. Natural Abs recognizing oligomeric Ab
assemblies have been found to reside in the human cer-
ebrospinal fluid, but at 30-230 times lower concentra-
tion than in plasma but the repertoires of IgG Abs are
the same in these two compartment [34]. IgG has been
s h o w nt ob i n dt oA b deposits in brain in AD patients
while a high IgG plaque labeling index was accompanied
with reduced plaque burden suggesting that auto-Abs
against Ab may help to control Ab burden [35].
Whether administration ofI V I G ,a sat h e r a p y ,c o u l d
further increase plaque labeling in patients with high
IgG plaque labeling index or compensate reduced pla-
que labeling in patiens with low IgG plaque labeling
index to further enhance the recognition and phagocyto-
sis of Ab deposits remains to be clarified. As presented
here, we studied the penetration of peripherally adminis-
tered exogenous IVIG into the brain and binding to Ab
deposits. By injecting human IgG into a mouse, we had
the opportunity to visualize the distribution of IVIG in
the mouse brain. We found that peripherally adminis-
tered IVIG reached the brain parenchyma with sufficient
concentrations to be detected, but that also significant
regional differences existed. The highest concentration
of human IgG was found in the septal hippocampus
with a clear declining gradient toward the temporal end
of this brain structure. Together with strong IgG
Figure 7 IVIG interacts with human-type Ab brain deposits in
APP/PS1 mouse brain after peripheral administration. Triple
immunofluorescence labelling of Ab deposits, human IgG and
microglia was performed after peripheral i.p. administration of IVIG.
Ab-immunoreactive deposits (A) and human IgG (B) was observed
to co-localize in the brain parenchyma, as revealed by confocal
laser-scanning microscopy imaged in the lateral entorhinal cortex
(D). Human IgG was detected predominantly within Ab plaques, but
also in blood vessels (B). Human IgG-bound Ab deposits were
surrounded by Iba-1 positive microglia (C, D). Merging the
immunosignals in (D) indicates that Ab deposits were targeted both
by human IgG and recruited microglia. The omission of primary
antibodies resulted in the expected absence of immunolabelling.
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cates that the primary access route of IVIG to the
mouse brain is through the choroid plexus.
To demonstrate the relevance of these findings in vivo,
we found peripherally administered IVIG to bind to Ab
deposits in the brain parenchyma. Human IgG-bound
Ab deposits were accompanied by closely surrounding
Iba-1 immunoreactive microglia. This suggests that
IVIG not only can bind to soluble oligomeric Ab species
and potentially prevent Ab fibrillization and toxicity, but
IVIG can also bind to pre-formed Ab deposits in vivo
and possibly contribute to reduction of Ab burden after
initial Ab deposition. As supported by our ex vivo data,
surrounding microglia may also contribute to Ab clear-
ance after IVIG administration in vivo.
Conclusions
The present data demonstrate that in addition to neuro-
protective effects, IVIG promotes recognition and
removal of natively formed human Ab deposits by
microglia. Our results suggest that natural Ab Abs in
IVIG interact with and promote the phagocytosis of Ab
deposits, resulting in enhanced microglia-mediated Ab
clearance. This has therapeutic relevance in vivo as we
found that peripherally administered IVIG penetrates
through the BBB and specifically binds to Ab deposits
in the brain parenchyma. These findings strongly sup-
port IVIG as a potential therapy to compensate the
deprivation of naturally occurring Ab Abs in AD that
could alleviate the Ab-induced toxicity.
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